US-based immuno-oncology company TCR2 Therapeutics Inc has completed a series B venture financing round co-led by 6 Dimensions Capital and Curative Ventures.

The company has raised $125m from the round, which also saw participation of new as well as existing investors.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The proceeds are intended to be used for advancing two TRuC-T cell programs through human proof-of-concept.

DBV Technologies SA has announced the pricing for its planned private placement of ordinary shares.

The company will place 2,135,737 shares priced at €34.71 ($42.68) a share as part of the placement to raise €74.13m ($91.16m) in gross proceeds.

Underwriters have been granted a 30-day option to purchase up to an additional 529,162 ordinary shares.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Proceeds are intended to be used to fund the development and commercialisation of Viaskin Peanut and advance development of other product candidates.

Part of proceeds will also be used for working capital and general corporate purposes.

“The offering includes 8.5 million shares priced at $41.50 a share to raise $352.8m in gross proceeds.”

Based in France, DBV Technologies is a biopharmaceutical company.

US-based biopharmaceutical company Arena Pharmaceuticals Inc has announced the pricing for its underwritten public offering of common stock shares.

The offering includes 8.5 million shares priced at $41.50 a share to raise $352.8m in gross proceeds.

Underwriters have been granted a 30-day option to purchase up to 1.275 million additional shares at the same price, less underwriter discounts, and commissions.

Proceeds are intended to be used for clinical and pre-clinical development of the company’s drug candidates, and for general corporate purposes.

Xencor Inc has announced the pricing for its proposed underwritten public offering of shares to raise $226.3m in gross proceeds to fund working capital and general corporate purposes.

Priced at $31 a share, the offering includes 7.3 million shares, while underwriters have been granted an option to purchase up to an additional 1.095 million shares to cover over-allotments.

Based in the US, Xencor Inc is a clinical-stage biopharmaceutical company.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Recognised with 2025 Excellence Awards for Research and Development and Marketing , Novotech converted FDA/EMA fast track designations into faster HDV trial timelines while translating complex HBV science into sponsor ready insights. Discover how this dual strength in execution and communication is reshaping liver disease clinical development.

Discover the Impact